• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method for producing cephalosporin derivatives of the formula (1) CO in the form of syn-isomers, where RJ is a hydrogen atom or methyl; RI is methyl, or K, and j j together - 1,3-numbered} C is methyl, allyl, 2-propinyl or carbethoxymethyl; the pyridinium substituent is bonded to sulfur at position 2; RVJ is a hydrogen atom or a hydroxy group, or a pyridinium substituent is bonded to sulfur in position 4; R4 is a hydrogen atom; H5 is a carboxy group, h 1 X® is an anhydrous or trifluoroacetic acid anion, or 85 anion is (X) of, characterized in that 7-amino-3-. Brommethyl-3-cephem-4-tri t-butylcarboxylate-5-xed is subjected to an interaction with an acid of formula (II)
    公开号:SU1165236A3
    申请号:SU823515897
    申请日:1982-11-15
    公开日:1985-06-30
    发明作者:Лабев Бернар；Сали Али
    申请人:Санофи (Фирма)；
    IPC主号:
    专利说明:

    TJI sy where RI and R have the indicated values, in an aprotic polar organic solvent medium at room temperature and the target product is isolated, where h 0 and the anion is COO, or where n 1 and X are hydrobromic acid anion, or where n 1 and X® is the anion of hydrobromic acid, is reacted with trifluoroacetic acid, followed by the separation of the target product, where L 1 and X is the trifluoroacetic acid anion.
    This invention relates to a method for preparing cephalosporin derivatives with bacteriostatic effects that can be used in medicine. The aim of the invention is to obtain new antibiotics of the cephalosporin series, which is characterized by a bacteriostatic activity. Compounds according to the invention have not been derived from a clear melting point, and some decomposition points do not allow characterization of them. . Therefore, the products are characterized by their nuclear magnetic resonance spectrum recorded at 60 MHz, the internal standard is hexamethyldisiloxane. The following abbreviations were used: S - singlet; D is a doublet; T triplet} Q - quadruple r; D, D - doublet of doublet; S, e - extended US GL; M - multiplet; AB - AB system; I represents a communication constant. In addition, elementary microanalyses are carried out in each case and are consistent with the indicated formulas. PRI me R 1. Trifluoroacetate 7- 2- (2-aminothiazole 4-b1) -2- (2-carboxy-2-propyxyxymino) -acetamndo2-3- (H-all-1-2-pyridino thiomersh1) -3 -cephem-4-carboxylic acid-8-oxide, syn-isomer (CM 40 874) JJ) RrRsrCH; R - C% CH CH; - R COOH-, (CG. A) H-allylpyridin-2-tion. A mixture of 5 g of 2-bromopyridine and 4.2 g of allyl bromide is heated at for 2 hours and 30 minutes. 10 ml of acetone are added and the crystals of methyl b-allyl-2bromopyridine are dehydrated, which is washed with acetone, then with ether and dried. A solution of potassium hydrogen sulfide was prepared by bubbling a stream of hydrogen sulfide into a solution of 2.6 g. Potassium in 40 ml of water until the bleaching of phenolphthalein. Then 2 g of the obtained product is added and stirred at 20 ° C for 15 minutes. Extract three times with 50 ml of methylene chloride, dry the solution on magnesium sulfate and evaporate the solvent to dryness. 1 g of N-allylpyridin-2thion is obtained in yellow oil. (B) (2-Tritylaminothiazolyl-4) 2- (2-tert-butoxycarbonyl-2-proxy-proxyimino) -2-acetamido-3-bromomethyl3-cephem-4-tert-butylcarboxyl-8-oxide (syn-isomer). To a solution of 5 g of 7-amino-3-bro-adyl-3-cephem-4-tertbutylcarboxylate-8-hydrochloride hydrochloride in 90 ml of methylene chloride was added 1.72 ml of triethylamine, 7.57 g of 2- (2-tetrylaminothiazolyl-4) -2- (2-tertbutoxycarbonyl-2-propyloxyimino) acetic acid, 2.84 g of dicyclohexylcarbodiimide and 0.1 g of hydroxybenzotriazole. The mixture is stirred for 15 hours at room temperature, then the formed dicyclohexyl urea is filtered. After evaporation of the solvent, the residue is chromatographed on a silica gel column (250 g). Wire eloirovanie with a mixture of hexane - ethyl acetate 50-50 (vol / vol), get 4.3 g of the expected product. Nuclear Magnetic Resonance Spectrum - (in solution in deuterated dimethyl sulfoxide): 1H at 8.70 ppm (NH-trit, S) - 1H at 8.07 ppm (NH-CO, D, Hz) - 15H at G 7.25 ppm (Ht rit, S-1 H at 6.72 ppm (H thiazole, S) - 1H at 5.88 ppm (Ng, DD, Hz, Hz) - tH at 4.96 ppm (Hb, 0, D) - 2H at 4.50 ppm (, AB, 1лв-12 Hz) - 2H at 3.77 ppm (CHj, 2, S, e. 9H at 1.45 ppm (-p-CH4S) with H , 1.37 ppm, (-C-, S) -9 N at 1.27 ppm (Hz b, (-C-CH, S). C) The syn-isomer of bromide 7 - f-2 (2-tritylaminothiaolyl -4) -2- (2-tertbutoxy arbon L-2-propyl siимno) acetamido-3- (N-allyl-2-pyridinothiomethyl) -3-cephem-4-tert-butyiжfarboxylate-5-oxide. e 3 hours at 20 ° C, a mixture and 0.7 g of a brominated derivative, prepared as described, and 0.14 g of H-all-1PIridine-2-thione in 4 ml of H, H-dimethylacetamide. The precipitate is added by addition of isopropyl ether and the solid is dried. a substance that is sprinkled with isopropyl ester 4. The solid is dissolved in a minimum of methylene chloride and chromatographed on a column of 20 g of silica gel. Carry out elution with a mixture of methylene chloride - methanol 90-. 10 (v / v), O, 65 g of the expected product is obtained. d) CM 40 874. Leaves for 45 minutes with a solution of 0.57 g of the product obtained in 6 ml of trifluoroacetic acid. It is concentrated in vacuo to approximately 3 ml, then precipitated by the addition of ether. The solid is dehydrated and dried. This gives 0.39 g of the expected product. Nuclear Magnetic Resonance Spectrum: 1H at 9.05 ppm (H, pyridine, D, Hz) - 1H at 8.50 ppc (CN CO D, 1-9 Hz) - 1H at 8.35 ppm (H (| , pyridine, M) III at 8.20 ppm (Nz.pyrididii, D, Hz) - 1H at 7.95 ppm vrTg-, pyridine, M) -411 between 7 and 10 ppm (2 COOH, NHjj) - 1H with; 6.82 ppm (H, thiazole, S) - 2H at 6.0 ppm (H7 and CH, M) - 5H between 5.0 and 5.6 ppm (CHNH, CH2 and H, M) at 4.5 ppni (CH. S7 A, AB, Hz) 1H at 4.32 ppm (, B, AB, 1 13 Hz) - 1H at 4.0 ppb (CHjS-O, A, AB, Hz) - tfi at 3.8 ppm (CH2S- 0 V of systems AB, Hz) -6H at 1.45 ru (- (). PR and M e p 2. Brs hydrochloride is fully 7- (2- (2-amyothiazolyl-4) -2-2 -carboxy-2-schyupiloximimo) -acet4-to-3- (H-allyl-2-pyridiniothiomethyl) -3-cephem-4-carboxylic acid-C, oxide, S-isomer (W 40 874 c) 1 Dissolve 9.3 g of the correct compound, obtained in Example 1c in 55 ml of 99% formic acid, then 3.3 ml of concentrated hydrochloric acid is added dropwise to slots and leave for 1 h chr {kreneshivayusch at. Filtration is complete (solid), which is washed with 25 ml of 50% formic acid. The filtrate is dried in vacuo at room temperature. The residue is dissolved in fOO ml absolutes ethanol and ssga sh) 1 steam bath under vacuum at a commat temperature. Dissolve the residue again in 50 ml of metaiol and expand at 30 ml of simple with a mix of water. ObevoAiv t precipitate and rinse it simple. 6.5 g of the expected product are obtained, which is promised by dissolving in 50 ml of methanol, the solution is poured at 1 per 4 hours {in 500 ml of simple efEf. dehydration and eventually get 6.2 g W 40,874 in. Nuclear magnetic resonance spectrum, about 1H at 9.10 ppb (Hg, pyridas, D, Hz) - 1H at 8.80 piMtt (NHCO, D, 1-9 Hz) - 1H at 8.35 ppm (H4, pyridine, T, Ha,) - 1H at 8.22 ppm (From, pyridine, D, Ha,} - 1H at 7.94 ppm (Well, pyridine. T, P;) 1B at 7.00 ppm (I, thiazole, S) - 2H at 6.00 ppm (Hj and -CH ", M) - 5H between 5 and 5.5 ppm (", CHjN, SNd M) - 2H at 4.45 ppm CGHgS, M) - 2H at 4, 00 (CHjS- O, M). P p and m ep 3. Internal salt of 7- (p- (2-aminothiazolyl-4) -2- (2-carboxy-2-propyloxyimino) -acetamido1 3- (H-allyl-2-pyridinothiame) -3 cephem-4 -carboxylic acid-8-oxide, (CM 40 874 a) syn-isomer. To a solution of 0.3 g CM 40 874 V obtained in Example 2, add 0.7 g of Amberlite ion exchange resin 1 R A 400 in the form acetate and stirred for 35 minutes at room temperature. The resin is filtered, then washed with water. The solution is evaporated to dryness in vacuum at room temperature. The residue is taken up in 10 ml of ethanol and evaporated to dryness in vacuum at room temperature. they peel off the residue with an ether and dehydrate the solid. After drying, 0.210 g of the expected inner salt is obtained. Nuclear Magnetic Resonance spectrum: 1H at 8.5 ppm (NHCO, D, Hz) IP at 8.0 ppm (H, pyridine, D, Hz) - 1H 7.45 ppm (H pyridine, D, Hz) - 1H at 7.30 ppm (H, pyridine, M) - 2H at 7.25 ppc j (N, H, S, e) - 2H at 6.80 ppm (H, thiazole + H5 pyridine, M) - 2H at 6.00 ppm (Nt and -CB, M) - 7H at 5.10 ppm (Hg,, CPzS-, Cji.j, M) - 1H at 4.25 ppm (, A, AB, 1d 17. Hz) - W at 3.80 ppm (, B of the AV system, Hz) 6H 1.45 ppm (- s: H). Examples 4-9. The method is carried out as in Example 1c, on the basis of the brilliantly manufactured Example 1b, and the type of pyridinthione used is varied. Then, by removing the protective groups of the compounds obtained as in Example Id, various compounds (1) are obtained, combined in Table 1. As can be seen from Table 1, in addition to the structure and characteristics of the products obtained t, experimental conditions are also indicated (the temperature and reaction time of the replacement of the bromo-derivative with the thione, KOToiXiie vary depending on the reagents used. Example 10. Trfluoroacetate (2-aminothiazolyl-4) - 2- (1-carboxy-1-cyclobutyl-1-amino) -acetamido D-3- (L-all-1 -2-pyridinium thiomethyl) -3-defem-4-carboxylic acid-8-oxide (CM 40914) sinisomer. (W) R, + RI (CH,),; R, CH2 CH-CH2; Rj COOH; X® CHZSOO; a) The syn isomer, - (2-tritylaminothiazolyl-4) -2- (1-tert-butoxycarbonyl-1-cyclobutyloxyimino) -atseta Ido-brometIL -3-3-cephem-4-carboxylate tert-8-oxide. In a solution of 4.4 g of 7-amino-3-brmmethyl-3-cephem-4-tert-butylcarboxylate-8-hydrochloride hydrochloride in 70 ml of anhydrous methylene chloride, in an atmosphere of nitrogen, 1.5 ml of triethylamine, 5.1 g of syn- isomers of 2- (2-tritylaminothiazolyl-4) -2- (1-tertbutoxyxyrbonyl-1-cyclobutyloximo ON) - ACETIC ACID 1, 2.4 g DICYCLOhexylcarbodiimide and 0.1 g dicyclohexylcarbodiimide and 0.1 g t-oxybeeimide and 0.1 g t-oxybeeimide and 0.1 g Stir for 1 hour at room temperature, then filter the dicyclohexyl urea formed and concentrate the solution to 20 ml in vacuo. Chromatographic on a column of silica gel (150 g). By elution with a mixture of hexane ethyl acetate 40-60 (v / v), 4.8 g of the expected product is obtained after evaporation of the solvent. Nuclear magnetic resonance spectrum: 1H at 7.90 ppm (NHCO, D, Hz) - at 7.26 ppm (H, aromatic, S) - 1H at 6.97 ppm (NH, trityl, 3.e) - 1H at 6.65 ppm (H, triazole S) - 1H at 6.18 ppm (H ,, DD, Hz, 5 Hz) - 2H at 3.4 ppm (CHg8-0, 8.e) - 6H between 1.5 and 2, 5 ppm (cyclobutyl, M) - 9H at 1.46 ppm S) COOC - CH3 - 9H at 1.36 ppm. COOC-CHj, S | b) The syn-isomer of bromide (2-tritylaminothiazolyl-4) -2- (1-tertbutoxycarbonyl-1-cyclobutyloxyimino) -acetamido-3- (M-allyl-2-pyridi-7-thiomethyl) -3-cephem-4-tert-butyl carboxylate. Using the bromo-derivative Example 10a and working as in Example 1c with H-allyl-2-pyridinethione, the expected compound is obtained in the form of a colorless substance. (c) CM 40 914; On the basis of this compound, the removal of cytosites is carried out, as indicated in example td. Nuclear Magnetic Resonance Spectrum: 1H at 9.05 ppc (H, pyridine D, Hz) - 1H at 8.20 ryut (U CO, D, Hz) - 3N between 7.6 and 8.5 ppm (H, H ( j, Hj, pyridine, M) 1H at 6.85 pryu (H, thiazole, S) - 2H at 6.0 ppm (HY and CH, M) - 1H at 6.85 ppm (H, thiazole, S) - 2H at 6.0 ppm (HI and CH, M) - 5H between 4.8 and 5.5 pp (Hb, CH2, CH.jN M) 2H at 4.40 ppm (CH, S, e) - 2H at 3.85 ppm (GHiS-O, S, e.) - 6H between 1.5 and 2.6 ppm (O, M). Examples 11-13. The method is carried out as in Example 10b, starting from the bromo-derivative of Example 10a and Changing the nature of the pyridinethione used. By removing the primer as indicated in the Id prize winner, compounds are obtained. (1), combining The data in Table 2 are approximate 14. The syn-isomer of the trifluoroacetate (2-aminothiazolyl-4 2- (1-carboxy-1-ethyloxyimino) -acet) amide I-3- (N-methyl-2-pyridiniotiethyl) -3-cephem -4-carboxylic acid-S oxide (CM 40800) (IV) Rj-H;; Rj-COOH; X CFjC6o. The method is carried out, as in Example 1, in the sin-isoner 2- (2-tri-1-aminothiazolyl -4) -2- (2 tert-butok sik arbonyl-2-propyloxnimo) -acetic acidic acid syn-isomero 2- (2-. Orthylaminothiazolyl-4) -2- (t-tert-butoxycarbonyl-1-ethyloxyimino) acetic acid . 368 cGadia with and d are carried out in the same way and the compound CM 40800 is obtained. Nuclear magnetic resonance spectrum: 1H at 9.0 ppm (Hg pyridine, M) —0.4 N at 8.65 ppm (ShSO, D, Hz) - 0, 6 N at 8.60 ppm (ShSO, D, Hz - 1H at 8.32 ppm (H, pyridine, M) - 1H at 8.10 ppm (Hz, pyridine, D, Hz - 1H at 7.80 ppm (Hf, pyridine, M) - 4H at 7.20 ppm (S, COOH, Se) - 0.6H at 6.82 ppm (H, thiazole, S) - 0.4 at 6.80 ppc (H, thiazole , S) - W at 5.92 ppc (Hf, 0D, 1.9 Hz, Hz) - 1H at 5.0 ppm (Hg, M) - 1H at 4.60 ppm. (JJj, M) - 1H at 4.50 ppm (SYAW, D, Hz) - (1H at 4.35 ppm (, D., Ha,) - 3N at 4.20 ppm (CH.IT S) - 1H at 4.0 ppm ( , D, Hz) - 1H at 3.87 ppm (SigZ-h O, D, Hz) - 3N at 1.4 ppm (N, M). CH3 Splitting of proton signals caused by the group - N1 - CO and thiazole shows that W 40 800 exists in the form of a mixture of 2-diastereoisomers, due to the asymmetry of the IMC with carbon in the oxin substituent.: Products (O was tested for their pharmacological activity, in particular on bacteriostatic activity. The bacteriostatic effect in vitro was determined in a solid medium by dilution methods. The results obtained are expressed in minimal inhibitory concentrations (CMI - mg / ml) and are related to various sources of enterobacteria and Peeudomonas. Comparisons obtained with 2 close products are presented as a comparison, namely: Syn-issjer. (2-aminothiazolyl4) -2-carboxymethoxyiminoacetamido73 (2-pyridylthiomethyl) -3-cephem-4-carboxylic acid-8-9 cis (compound A) The syn-isomer of trifluoroacetate (2-aminothiazolyl-4) -2 - (2-carboxy-2-propyloxy) o) acetamido - 3 N-gC-C-Shh D'L f ch, t-O O-COOH
    The results are summarized in 3.
    As can be seen from the table. 3, the proposed ts products are active on enterobacteria and Faoudomonas, which are insensitive to antibiotics of the cephalus sporium type.
    Regarding the reference product A 20, the product (O is active on the following sources: CitTobacter, Enterobacter, Serratia and Pseudomonas, maintaining activity at least equal to the activity of the reference product on Kleb-25iella and Proteus.
    In relation to the reference product B, products (1) are more active on Citrobacter, Proteus, Enterobacter, the activity of such a time is different in other sources, and sometimes even higher.
    Consequently, the products according to the invention are non-toxic and can be used as antibiotics in nursing or veterinarian bacterial infections 1 with susceptible microbes.
    The pharmaceutical compositions are prepared from compounds (1) in their acidic form or when the solubility is not sufficient in salt form.
    Pharmaceutical compositions can be solid or liquid and can be, for example, in the form of tablets, congealed formulations, granules, ointments, creams, gels or injectable preparations.
    The dosage of the preparation depends on the type of infection and on the method of administration, in particular for an adult when injected, it is 0.250 g and 4 g per day.
    As an example of the proposed pharmaceutical composition, it is possible to prepare ampoules for injecting) containing: 1 g of W 40874 in 5 ml of water | w for an injectable preparation, a sufficient amount of sodium carbonate for pp 6.3. - (M-methyl-2-pyridinothiomethyl) 3-cephem-4 -carboxylic acid (compound b). S f - € H2 $ CFgCOO Soon
    .
    A0763
    H
    CH,
    Table 1
    CFjCOO
    1H at ppm (Bg, pyridine, D, Hi) - 4H between-DU 7.60 and 8.60 ppm (NHGOi H, H, Hj pyridine, M) IH at 6.83 pps (H, thiazole, S) - tH
    at 5,97 pps (B ;, M) IH
    0-24 at 5.00. ppm (Hg, D, IA Hz - 2H at A, joint-stock company ppm (CH2S, Se) -3H at A, 20 ppm (CH, -N, S) - 2H at 3.80 P1NR (CH ,,. Se) - 6H at 1, A6 ppm / CH,
    (-sH S).
    CH,
    2H at 8.6A ppm (H, pyridine, D, 1-7 Hz) - IH at 8 AO ppm (NHCO, D, 1-9 Hz). - 2H at 7.95 ppm (H, Hf, pyridine D, I-7 Hz) - AH at. 7.50 ppm (NH ,, 2 COOK, S, e.) - IH at 6.80. ppm (H, thiazole, S) - IH at 5.95 ppm (H, D, D, I, -9 Hz), Hz) Z
    eight
    1H at 9i2 ppm (NHCO, D, I «9 Hz) - 4H between 7.5 and 8.8 ppm (H„ H4, HS and H, pyridine, M) - 1H at 6.90 ppm (H, thiazole, S) 1H at 6.0 ppim (H7, M) 2H at 5.67 ppm (Se). Continuation of the table.1 7 -1H at 5.05 ppm (Hg, D, Hz) - 1H at 4.40 ppm (CHgS A of AB, 1dv 13 Hz) W at 4.35 ppm (CHjS, B, AV, Hz) - 3N at 4.16 pp m (CH, N, S) - 1H at 3.89 ppm CCggS- O, A , AB, 1. Hz) - 1H at 3.76 ppm (, B, AB, Hz) - 6H at 1.43 ppm CH 3 (-C., 2D). . 5H from 7.5 to 9, t ppm (H, H4, H and Hg, pyridine and NHCO, M) - 1H at 6.85 ppm (H, thiazole, S) - 1H at 6.0 P1NP (Well, M ) - 2H at 5.65 ppc (CHjN, M) OZ at 5.0 ppm (Hfc and CHjS, M) - 2H at 3.95 ppm CHj8-0, Se) - 6H at 1.43 ppm (-C , S) ESN covered with dimethyl sulfoxide 5H between 6.5 and 10 ppm (H, N, 2 COOH, OH M) - 1H at 8.60 ppm (H pyridine, M) 1H at 8.45. ppm (NHCO, D,) - 2H at 7.9 ppm - 2H at 7.9 ppm (H and Hg - pipipin. M) - (H and Hj, pyridine, M) - 1H at 6.80 ppm (H , thiazole, S) 1H at 6.0 (H, M) 1H W at 4.96 ppc (Hg, D, Hz) - 5H at 4.30 ppm 1ts - jn at 4, ju (CHjN® and CHaS, M ) - 2H at 3.85 rtu (CH2S- 0, M) 6H at 1.47 ppm / CH, CH3
    41607 -CHg-CH-CHg H
    eleven
    S) (-Sn,
    1, 20 ppm
    T, (SHUSN CH,
    2H at 8.70 ppm (H, l, pyridine, D, Hz) - 1H at 8.45 ppm (NHCO, D, Hz) 2H at 8.0 ppm (H, pyridium, D, Hz) - 1H at 6.80 ppb
    0- (2) (H, tiazop, S) - 2H at
    V11) I pause f f
    6.0 ppb (Well + CH, M) - 2H at 5.40 ppm (Cii, M) f OZ at 5.05 ppm (M) - 2H at 4.45 ppm (SNGZ, M) - 2H at 3, 80 ppm (CHiS-H), AB, Hz) - 6H at 1.45 ppm (C-CCH XjjZS)
    9H Ie 7.5 and 9.5 ppm (NHj, COOJ NHCO, Hj, H4: Well and H is pyridine, M) - 1H at 6.88 ppm (H - thiazole, S) - 1H at 6.0 - p / rt
    A0882
    CH,
    12
    40954
    CH
    AND
    13
    41647-CH. H
    0- (5 h) (N ,, M) - 1H at 5.07 ppm (Nb. D, Hz) - 2H at 4.45 pt (, M) - 3N at 4.25 ppm (SND, N®- , S) 2H at 3.93 ppm (CHjS- O, M) - 6H between 1.5 and 2.7 ppm (OM).
    7H between 8.3 and 9.0 ppm (NHCO, NHz, 2СООД, Н, and Н, pyridine, M) i. - 2H at 7.90 ppm (Hj and Well, pyridine, D, Hz) - 1H at 6.82 ppm (H, thiazole, S) 1H at 6.0 ppm (H, DD).
    0- (16 h) (Hz), 12-5 Hz) - 1H at 5.0 ppm (H, D, 1 5 Hz) - 2H at 4.40 ppm (CHjS, S, e) - 3N at 4, 20 ppm (CH, - N®, S) - 2H at 3.80 ppm (, Se) - 6H between 1.5 and 3 ppm (O, M)
    1NPr 8.80 ppm (W-CO, D, Hz) - 2H at 8.70 ppm (H, Bc, pyridine, D, Hz) 2H at 8.0 ppm (H l, pyridine, D, Hz) - 1H at 6.80 ppm (H, thiazole, S) 2H at 6.00 ppm
    0- (1 h) (H7 + CH, M) - 2H at
    5.40 ppm (C.H2, M) - 3N at 5.05 ppin (Hg + qi N®, M) pp 4.4S pto GPN-Ya M LP at h, 43 pprSh LNdO, I;
    2H at 3.80 ppm (CH2 &, AB, Hz) - 4H at 2.45 ppm
    .COOH (, M)
    CH2r-t
    2H at 1.90 ppm (CH 4). Citrobacter 49 44 Prote 0, 0.25 us 1510 0.031 iO, 125 Serra0, 25 2 J tia RL 72 0.5 0.25 Klebsiel1a RO 30 0.25 iO, 125 0.25 0.125 0.25 robafcter RO 46 0, 5 0.25 0.5 0.25 0.25 robacter P 99 0.5 0.5 0.25 1 udonionas A22 tP 88 uddmonas RL 112 88 48
    T a b, l and c a 3 12 16 20.5 16 8 4 0.125 0.125 0.25 0.25 4 0.25 0.25 2 32 2 O, 125 0.1250.5 0.5 0.25 0 , 25 0.1251 8 64 0.5 0.5 2 16 256 25 "8 2 256 16 4
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING CEPHALOSPORIN DERIVATIVES of formula (1)
    R4 s-soon and
    NR, t 1 1
    O-S-COOP
    I I 2 in the form of syn-isomer, where R, and have the indicated meanings;
    Tg is a protecting group such as ’trityl; about
    P is a protecting group such as tert-butyl in the presence of an organic amine, dicyclohexylcarbodiimide and oxybenzotriazole in an aprotic polar organic solvent at room temperature, the resulting product is reacted with pyridin-2-thione or with pyridine, 4-thione of formula (III) or (1V) □ 5 particonical solvent at room temperature and isolate the target product, where I = 0 and - anion - С00 or where η = 1 and X е - anion of hydrobromic acid, or the target product, where η = 1 and Χ θ is the anion of hydrobromic acid, subjected to interaction with trifluoroacetic acid, followed by isolation of the target product, where P = 1 and X e is the anion of trifluoruk. acetic acid.
    where R v and have the indicated meanings in an aprotic polar organ
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1165236A3|1985-06-30|Method of obtaining cephalosporin derivatives
    US4464367A|1984-08-07|Cephalosporin derivatives, process for preparation thereof and drugs containing said derivatives usable as antibiotics
    CA2068567A1|1992-11-21|Amide esters of rapamycin
    FR2511682A1|1983-02-25|CEPHALOSPORINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    CS209878B2|1981-12-31|Method of making the new alcyloxime derivatives of the 7-/2-|acetamido/cephalosporan acid
    GB2111482A|1983-07-06|Azetidine medicaments
    CS235508B2|1985-05-15|Method of new 7-amino-3-formylmethyl-cephalosporine derivatives production
    FI63586C|1983-07-11|PROCEDURE FOR THE FRAMSTATION OF AV 7-BETA- | -3- | -3-CEFEM-4-CARBOXYLSYROR WITH ANTIBACTERIAL NETWORK
    KR20210120070A|2021-10-06|immunomodulators
    IE52767B1|1988-02-17|Antibiotic derivatives, derived from cephalosporins
    US4609654A|1986-09-02|Derivatives of cephalosporins substituted in 3 position by a thiomethyl heterocycle group; and pharmaceutical compositions containing them
    FI75168C|1988-05-09|Process for preparing sodium cephuroxim or a solvate therein and sodium cephuroxim tetrahydrofuran solvate useful as an intermediate in the process.
    SU1194280A3|1985-11-23|Method of producing cephalosporin derivatives
    KR100696422B1|2007-03-20|Cephalosporines having cyclic aminoguanidine substituents as antibiotics
    IE51358B1|1986-12-10|1,2,4-triazinylthiomethyl-3-cephem sulfoxides,process for their preparation and pharmaceutical compositions containing them
    US3868369A|1975-02-25|3-heterocyclicthiomethylcephalosporins
    US3963711A|1976-06-15|Cyanomethyl sulfinyl- and sulfonyl-acetamido cephalosporins
    US3957770A|1976-05-18|Substituted acetamidocephalosporins
    US4497811A|1985-02-05|1-Oxadethiacephalosporin compound and antibacterial agent containing the _same
    US4013765A|1977-03-22|Compositions and methods for treating bacterial infections with substituted acetamidocephalosporins
    EP0098615B1|1988-01-07|1-oxadethiacephalosporin compound and antibacterial agent containing the same
    US3998818A|1976-12-21|Trifluoroethylmercapto, -sulfinyl or -sulfonyl acetamidocephalosporins
    US3998819A|1976-12-21|Trifluoroethyl-mercapto, -sulfinyl or -sulfonyl acetamidocephalosporins
    DE2950990A1|1980-06-19|7 ALPHA METHOXYCEPHALOSPORINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM
    SU419040A3|1974-03-05|Method of producing derivatives of 7-acylaminoacetophosphoric acid
    同族专利:
    公开号 | 公开日
    YU253782A|1984-12-31|
    KR840002407A|1984-07-21|
    ES8405807A1|1984-06-16|
    SU1276263A3|1986-12-07|
    FR2516515A1|1983-05-20|
    PL239045A1|1984-02-27|
    AU566027B2|1987-10-08|
    EG15642A|1986-09-30|
    HU187812B|1986-02-28|
    EP0088853A1|1983-09-21|
    OA07253A|1984-04-30|
    GR76748B|1984-08-30|
    PL136539B1|1986-02-28|
    SG2289G|1989-06-02|
    NZ202493A|1985-11-08|
    IL67208A|1986-03-31|
    PL136099B1|1986-01-31|
    JPS5890590A|1983-05-30|
    IL67208D0|1983-03-31|
    DK499382A|1983-05-17|
    SU1318145A3|1987-06-15|
    DE3275649D1|1987-04-16|
    KR880001816B1|1988-09-19|
    ES517393A0|1983-12-01|
    CS232740B2|1985-02-14|
    FI823917L|1983-05-17|
    IE822665L|1983-05-16|
    PL244233A1|1984-06-18|
    PL136101B1|1986-01-31|
    MA19644A1|1983-07-01|
    FI74710B|1987-11-30|
    PL244232A1|1984-06-18|
    IE54068B1|1989-06-07|
    US4593022A|1986-06-03|
    CS810682A2|1984-02-13|
    FI74710C|1988-03-10|
    ZA828388B|1983-10-26|
    AT25847T|1987-03-15|
    ES526001A0|1984-06-16|
    CA1201432A|1986-03-04|
    NO823740L|1983-05-18|
    ES8401082A1|1983-12-01|
    EP0088853B1|1987-03-11|
    ES8405806A1|1984-06-16|
    PT75854A|1982-12-01|
    FR2516515B1|1984-11-23|
    AU9049982A|1983-05-26|
    FI823917A0|1982-11-16|
    ES526002A0|1984-06-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2716677C2|1977-04-15|1985-10-10|Hoechst Ag, 6230 Frankfurt|Cephem derivatives and processes for their preparation|
    DE2857196C3|1977-04-19|1981-04-16|CIBA-GEIGY AG, CH 4002 Basel|Block dyeing method|
    GB1604723A|1978-05-26|1981-12-16|Glaxo Operations Ltd|7--2-oxyimino-acetamido)-cephem derivatives|
    GB1604724A|1978-05-26|1981-12-16|Glaxo Operations Ltd|7--2-oxymino-acedamido)-cephem derivatives|
    AR229882A1|1978-05-26|1983-12-30|Glaxo Group Ltd|PROCEDURE FOR PREPARING CEPHALOSPORIN ANTIBIOTICS|
    GB2027691B|1978-05-26|1983-03-02|Glaxo Group Ltd|Cephalosporin antibiotics|
    GB2036738B|1978-11-17|1983-01-19|Glaxo Group Ltd|Cephalosporin antibiotics|
    AU531801B2|1978-11-17|1983-09-08|Glaxo Group Limited|Chphalosporin antibiotics|
    GB2046261B|1979-03-22|1983-07-20|Glaxo Group Ltd|Cephalosporin antibiotics|
    FI800889A|1979-03-22|1980-09-23|Glaxo Group Ltd|KEFALOSPORINANTIBIOTIKA|
    US4237128A|1979-04-12|1980-12-02|E. R. Squibb & Sons, Inc.|7-[2--2-[alkoxyimino]acetamido]cephem sulfoxides|EP0115770B2|1983-01-07|1996-06-19|Takeda Chemical Industries, Ltd.|Thiazole Derivatives|
    US4855420A|1983-06-03|1989-08-08|Ici Pharma|Cephalosporin derivatives|
    GB8413152D0|1983-06-03|1984-06-27|Ici Pharma|Cephalosporin derivatives|
    US4785090A|1984-02-23|1988-11-15|Meiji Seika Kaisha, Ltd.|Cephalosporin derivatives|
    JPH0521912B2|1984-02-23|1993-03-25|Meiji Seika Kk|
    FI851934L|1984-05-30|1985-12-01|Ici Plc|KEFALOSPORINDERIVAT.|
    JPH0522719B2|1984-07-03|1993-03-30|Meiji Seika Kk|
    US4868173A|1984-11-20|1989-09-19|Ici Pharma|Cephalosporin derivatives|
    US4761410A|1985-01-14|1988-08-02|Fujisawa Pharmaceutical Co., Ltd.|Cephem Compounds|
    US4645769A|1985-03-01|1987-02-24|Merck & Co., Inc.|1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same|
    US4812562A|1985-07-25|1989-03-14|Taisho Pharmaceutical Co., Ltd.|Cephalosporin derivatives|
    JPH064645B2|1985-11-27|1994-01-19|明治製菓株式会社|Novel cephalosporin derivative and antibacterial agent containing the same|
    US5359057A|1986-02-07|1994-10-25|Hoffmann-La Roche Inc.|Acylation of amines|
    US4880797A|1986-03-20|1989-11-14|Banyu Pharmaceutical Co., Ltd.|Cephalosporin derivatives and antibacterial agents|
    AT81656T|1986-03-20|1992-11-15|Banyu Pharma Co Ltd|CEPHALOSPORINE COMPOUNDS, METHOD FOR THEIR PRODUCTION AND ANTIBACTERIAL AGENTS.|
    WO1991005789A1|1987-03-20|1991-05-02|Banyu Pharmaceutical Co., Ltd.|3-[thiomethyl]-cephalosporin derivatives|
    JPS63154622A|1986-12-18|1988-06-27|Meiji Seika Kaisha Ltd|Antimicrobial agent containing cephalosporin derivative as active ingredient for mammal|
    KR940000112B1|1990-07-05|1994-01-05|주식회사 대웅제약|3-substituted cephem compounds|
    CA2828114A1|2010-02-26|2011-09-01|Gary Igor DMITRIENKO|Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    FR8121385A|FR2516515B1|1981-11-16|1981-11-16|
    [返回顶部]